Endologix LLC - Strategic SWOT Analysis Review

Endologix LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The analyst’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Endologix LLC (Endologix) is a medical equipment company. It develops solutions for vascular diseases, focusing on unmet clinical needs and specialized anatomical challenges. Its endovascular repair (EVAR) portfolio includes advanced devices like ALTO, which features adaptive sealing technology and AFX2, which preserves the native bifurcation with ActiveSeal technology. The company also leads in procedural training through virtual reality-based EVAR programs. In peripheral artery disease, it offers percutaneous transmural arterial bypass therapy with the DETOUR System, utilizing the Endocross Device and Torus Stent Graft to restore blood flow and resist forces at critical anastomosis sites. Endologix is headquartered in Irvine, California, the US.

Endologix LLC Key Recent Developments

• Jan 07, 2025: Endologix Announces Leadership Transition
• Jun 18, 2024: Endologix Appoints Graham Phillips as Chief Operating Officer
• Mar 14, 2024: Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit
• Mar 05, 2024: Endologix Appoints Mike Mathias as Chief Commercial Officer

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.